A patient stratification signature mirrors the immunogenic potential of high grade serous ovarian cancers
STRATsig is a composite of parallel immunoregulatory pathways that mirrors tumor immunogenic potential. Approximately one-third of HGSC cases classify as S-T3 and display a hypo-immunosuppressed and antigenic molecular composition that favors immunologic tumor control. These patients may show heightened responsiveness to current immunotherapies.
Authors
- Calvin J. Wagner
- Lance David Miller (ORCID: https://orcid.org/0000-0003-3799-2528)
- Laurel K. Berry (ORCID: https://orcid.org/0000-0002-2437-7764)
- Julia Chifman (ORCID: https://orcid.org/0000-0002-7520-0627)
- Ashok Pullikuth (ORCID: https://orcid.org/0000-0002-0041-3310)
- Raghvendra Mall (ORCID: https://orcid.org/0000-0003-1779-3150)
- Ming Sum Leung
- Janelle Darby (ORCID: https://orcid.org/0000-0003-3410-5364)
- Michael Kelly (ORCID: https://orcid.org/0000-0001-7955-3860)
- Kristen Stearns (ORCID: https://orcid.org/0000-0002-3634-0758)
- Jeff W. Chou
- Yuezhu Wang (ORCID: https://orcid.org/0009-0004-9175-2589)
Institutions
- Atrium Health Wake Forest Baptist (US)
- St. Jude Children's Research Hospital (US)
- American University (US)
- Technology Innovation Institute (AE)
- Wake Forest Baptist Comprehensive Cancer Center
- Wake Forest University (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1186/s12967-024-05846-9
- Citations
- 4
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- University of Otago
- Comprehensive Cancer Center at Wake Forest Baptist Medical Center
- Sidra Medicine
- Birla Institute of Scientific Research
- Wake Forest School of Medicine
- National Cancer Institute